Carbamazepine
| Evidence Level: L5 | Predicted Indications: 3 |
Table of Contents
- Carbamazepine
- Pharmacist Assessment Report
- Carbamazepine: Voltage-gated sodium channel blocker → trigeminal nerve neoplasm
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- India Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Carbamazepine: Voltage-gated sodium channel blocker → trigeminal nerve neoplasm
One-Sentence Summary
Carbamazepine is a sodium channel–blocking medicine used mainly in seizure and neuropathic pain disorders. The TxGNN model predicts it may be effective for trigeminal nerve neoplasm, but there are no registered clinical trials and the 19 publications retrieved are mostly case reports and reviews of tumour-related trigeminal neuralgia, not studies of treating the tumour itself.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | trigeminal nerve neoplasm |
| TxGNN Prediction Score | 1.0000 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data |
| Number of Listed Products | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Carbamazepine is generally understood to act by blocking voltage-gated sodium channels, which calms abnormal nerve firing. This is why it is widely used for trigeminal neuralgia, a nerve pain condition.
The link to the predicted disease is weak. The literature describes patients whose trigeminal neuralgia was caused by tumours or other lesions near the trigeminal nerve (schwannoma, meningioma, lymphoma, lipoma, dermoid cyst, pituitary adenoma). In these reports carbamazepine was given for pain, and in several cases it stopped working as the lesion grew. Nothing retrieved suggests that carbamazepine shrinks or controls a tumour. The very high score most likely reflects the drug’s close association with trigeminal neuralgia rather than a new anti-tumour opportunity.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
No retrieved publication studies carbamazepine as a treatment for trigeminal nerve neoplasm itself. The most relevant items are listed below.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 36824641 | 2022 | Review | Acta Clin Croat | Treatment options for trigeminal neuralgia, including tumour-related causes |
| 17997704 | 2007 | Review | Expert Rev Neurother | Medical and surgical treatments for trigeminal neuralgia |
| 30741017 | 2023 | Case report | Br J Neurosurg | Primary lymphoma of the trigeminal nerve; carbamazepine did not improve facial pain |
| 25433061 | 2014 | Case report | No Shinkei Geka | Cerebellopontine angle lipoma with trigeminal neuralgia; pain poorly controlled and side effects on carbamazepine |
| 15235745 | 2004 | Case report | Arq Neuropsiquiatr | Primary melanoma of Meckel’s cave; pain not relieved by carbamazepine |
| 25142539 | 2014 | Case report | Rinsho Shinkeigaku | Lymphoma spreading along the trigeminal nerve; initial pain response to carbamazepine, later ineffective |
| 33989821 | 2021 | Case report | World Neurosurg | Petroclival meningioma causing trigeminal neuralgia, treated by surgery |
| 32454201 | 2020 | Case report | World Neurosurg | Endoscopic resection of a trigeminal schwannoma in the pterygopalatine fossa |
| 3181365 | 1988 | Preclinical | Exp Neurol | Carbamazepine inhibited spontaneous activity in experimental rat neuromas (nerve injury model, not tumour) |
| 11286444 | 2001 | Survey | Br J Oral Maxillofac Surg | Survey of how surgeons investigate and medically manage trigeminal neuralgia |
India Market Information
Carbamazepine is marketed in India, with single-ingredient oral products on the market. The licence list below may be partial.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 18656 | Ametol 200mg Tablet | Strip of 10 tablets | Not recorded |
| 92152 | Fobigone 200mg Tablet | Strip of 10 tablets | Not recorded |
| 24134 | Arilep 200mg Tablet SR | Strip of 10 tablets SR | Not recorded |
| 234021 | Versitol 200mg Tablet | Strip of 10 tablets | Not recorded |
| 214822 | Tegrital 200 Tablet | Strip of 10 tablets | Not recorded |
Safety Considerations
- Drug Interactions: 377 interactions were found in the interaction database. Examples of major-level interactions include clarithromycin and eliglustat. Moderate-level examples include doxycycline, hydrocortisone, dexamethasone, bupropion, morphine, metronidazole, cimetidine and pioglitazone.
Please refer to the package insert for warnings and contraindications, as these are not available in the data compiled for this report.
Conclusion and Next Steps
Decision: Hold
Rationale: No cited study examines carbamazepine for trigeminal nerve neoplasm itself. The literature only covers tumour-related trigeminal neuralgia, where carbamazepine treats pain, not the tumour. The high score is not backed by trial or anti-tumour evidence, so the evidence level is L5.
To proceed, the following is needed:
- Evidence of an anti-tumour effect, from preclinical or clinical studies
- Detailed mechanism of action data
- Package insert warnings and contraindications for safety review
- A clear definition of whether the goal is pain relief in tumour patients (which is symptom control, not a new disease indication) or tumour treatment
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.